Incyte's Q2 2020 financial results showed a 16% increase in product and royalty revenues compared to the prior year, driven by growth in Jakafi net product revenues and higher product royalty revenues from Jakavi and Olumiant. The company reaffirmed its full-year 2020 financial guidance and highlighted key clinical program updates, including positive data for parsaclisib in combination with ruxolitinib in myelofibrosis patients and the FDA approval of Monjuvi for relapsed or refractory DLBCL.